Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b/2a, randomized, single-blind, single-center study to determine safety and pharmacodynamic of LSTA1 in combination with durvalumab, nab-paclitaxel and gemcitabine versus standard-of-care alone in patients with locally advanced non-resectable Pancreatic ductal adenocarcinoma

Next Previous
Trial Profile

A phase 1b/2a, randomized, single-blind, single-center study to determine safety and pharmacodynamic of LSTA1 in combination with durvalumab, nab-paclitaxel and gemcitabine versus standard-of-care alone in patients with locally advanced non-resectable Pancreatic ductal adenocarcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cerepetide (Primary) ; Durvalumab; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms iLSTA Trial

Most Recent Events

  • 07 Aug 2025 According to a Lisata Therapeutics media release, final data and key findings from this study are anticipated in the first quarter of 2026.
  • 17 Jul 2025 Results presented in the Lisata Therapeutics Media Release.
  • 17 Jul 2025 According to a Lisata Therapeutics media release, updated preliminary data from this trial was presented at the 2025 ESMO Gastrointestinal Cancers (ESMO-GI) Congress on July 3, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top